March 10, 2017 / 9:45 PM / 4 months ago

BRIEF-Crispr Therapeutics Q4 earnings per share $0.40

1 Min Read

March 10 (Reuters) - Crispr Therapeutics AG:

* Crispr Therapeutics reports fourth quarter and full year 2016 financial results and provides business update

* Crispr Therapeutics -on track to file its clinical trial authorization in Europe by year-end 2017 for lead therapeutic product to treat beta-thalassemia

* Crispr Therapeutics - expects existing cash resources will enable co to fund operating expenses, capital expenditure requirements for at least next 2 years

* Qtrly earnings per share $0.40

* Qtrly collaborative revenue $2.3 million versus $247,000 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below